文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

糖皮质激素治疗COVID-19肺炎(CORTIVID):随机对照试验方案结构摘要

Treatment of COVID-19 pneumonia with glucocorticoids (CORTIVID): a structured summary of a study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2021-01-11

CORTIVID是一项在西班牙两家医院开展的平行组四盲随机对照试验,评估甲泼尼龙静脉冲击治疗对伴有炎症标志物升高的COVID-19肺炎患者14天治疗失败率的影响。计划纳入72例患者,按年龄分层区组随机分配至标准治疗联合甲泼尼龙组或标准治疗联合安慰剂组。

要点

  • 纳入标准包括症状≥7天、CRP>60 mg/dL或IL-6>40 pg/mL或铁蛋白>1000 μg/L。
  • 主要结局为随机后14天治疗失败率,包括死亡、ICU入住、机械通气等。
  • 甲泼尼龙方案为第1-3天每日静脉输注120 mg,安慰剂为0.9%氯化钠100 mL。

核心结论

  • 该研究旨在评估糖皮质激素冲击治疗能否改善伴有炎症标志物升高的COVID-19肺炎患者的临床结局,目前尚在招募中,无疗效结论。

研究设计与样本

  • 平行组、四盲(患者、干预提供者、结局评估者和数据管理者)、随机对照试验,在西班牙两家医院进行。
  • 计划纳入72例因COVID-19肺炎住院的成年患者,按年龄(<75岁或≥75岁)分层区组随机,区组大小4和6。
  • 样本量基于对照组治疗失败率35%、干预组10%的假设,双侧α=0.05、β=0.2,估计需60例,考虑20%失访后为72例。

主要发现

  • 原文未报告研究结果,仅报告了方案设计和招募状态。

关键数值与推荐

  • 纳入标准:年龄≥18岁;RT-PCR确诊SARS-CoV-2肺炎;症状≥7天;住院;CRP>60 mg/dL、IL-6>40 pg/mL和/或铁蛋白>1000 μg/L;签署知情同意。
  • 排除标准包括:SpO2<90%(环境空气)或PaO2<60 mmHg或PaO2/FiO2<300 mmHg;正在使用糖皮质激素或其他免疫抑制剂;失代偿糖尿病;未控制高血压等。
  • 干预组:标准治疗+甲泼尼龙第1、2、3天每日静脉输注120 mg;对照组:标准治疗+安慰剂(0.9%氯化钠100 mL)第1、2、3天每日静脉输注。
  • 主要结局:随机后14天治疗失败率,治疗失败定义为死亡、需ICU入住、开始机械通气、SpO2<90%或PaO2<60 mmHg或PaO2/FiO2<300 mmHg(非COVID-19其他原因解释)和/或PaO2较基线下降≥15%并伴实验室和影像学恶化。

临床怎么用

  • 该方案为伴有炎症标志物升高的COVID-19肺炎患者使用短期甲泼尼龙冲击治疗提供了随机对照试验框架,结果待发表后可用于指导临床决策。

局限性

  • 样本量较小(72例),可能限制统计效能和亚组分析。
  • 试验在西班牙两家医院进行,外推性需谨慎。
  • 原文未报告研究结果,无法评估疗效和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of this study is to assess the effectiveness and safety of glucocorticoid infusion pulse therapy to improve the clinical outcomes of patients with COVID-19 pneumonia with elevated inflammatory biomarkers. TRIAL DESIGN: A parallel-group quadruple-blind (participant, intervention provider, outcome assessor and data manager), randomised controlled trial. PARTICIPANTS: All patients admitted to hospital due to COVID-19 pneumonia will be considered eligible. Potential candidates will be identified and consecutively included in the emergency room or in the COVID-19 admission wards of two hospitals in Spain: Complejo Hospitalario de Navarra (Pamplona) and Hospital Moisès Broggi (Sant Joan Despí, Barcelona). Inclusion criteria are: 1) age ≥18 years old; 2) diagnosis of SARS-CoV-2 pneumonia confirmed by reverse transcriptase polymerase chain reaction (RT-PCR) of nasopharyngeal swabs or sputum in accordance with the recommendations of the Spanish Ministry of Health; 3) history of symptoms compatible with COVID-19 ≥7 days; 4) hospital admission; 5) at least one of the following: C-reactive protein (CRP) >60 mg/dL, interleukin-6 (IL-6) >40 pg/mL, and/or ferritin >1000 μg/L; and 6) provision of informed consent. Exclusion criteria are: 1) allergy or contraindication to any of the drugs under study; 2) oxygen saturation (SpO2) <90% (in air ambient) or partial pressure of oxygen in arterial blood (PaO2) <60 mmHg (in ambient air) or PaO2/FiO2 <300 mmHg; 3) ongoing treatment with glucocorticoids, or other immunosuppressants, including biologics for another indication; 4) decompensated diabetes mellitus; 5) uncontrolled hypertension; 6) psychotic or manic disorder; 7) active cancer; 8) pregnancy or breastfeeding; 9) clinical or biochemical suspicion (procalcitonin >0.5 ng/mL) of active infection other than with SARS-CoV-2; 10) management as an outpatient; 11) conservative or palliative management; 12) participation in another clinical trial; or 13) any major uncontrolled medical, psychological, psychiatric, geographic or social problem that contraindicates the patient's participation in the trial or hinders proper follow-up and adherence to the protocol and evaluation of study outcomes. INTERVENTION AND COMPARATOR: Eligible patients will be randomised to receive standard of care plus methylprednisolone (intervention group) or standard of care plus placebo (control group). Intervention group: standard of care at the discretion of the researcher, including lopinavir/ritonavir (200/50 mg, 2 tablets twice daily, per os, for 7 to 14 days) ± remdesivir (a single intravenous loading dose of 200 mg on day 1 followed by once-daily intravenous maintenance doses of 100 mg from day 2 to 5), or no drug treatment, + methylprednisolone (once-daily intravenous infusion of 120 mg on days 1, 2 and 3). CONTROL GROUP: standard of care at the discretion of the researcher, including lopinavir/ritonavir (200/50 mg, 2 tablets every 12 hours, per os, for 7 to 14 days) ± remdesivir (a single intravenous loading dose of 200 mg on day 1 followed by once-daily intravenous maintenance doses of 100 mg from day 2 to 5), or no drug treatment, + placebo (once-daily intravenous infusion of 100 mL of 0.9% saline on days 1, 2 and 3). MAIN OUTCOMES: The primary outcome is the proportion of patients with treatment failure at 14 days after randomisation, defined as: 1) death, 2) need for admission to an intensive care unit (ICU), 3) initiation of mechanical ventilation, 4) SpO2 falling to <90% (in ambient air) or PaO2 <60 mmHg (in ambient air) or PaO2FiO2 <300 mmHg, not explained by a cause other than COVID-19, and/or 5) decrease in PaO2 ≥15% from baseline, together with laboratory and radiological deterioration. RANDOMISATION: Treatment will be allocated by block randomisation stratified by patient age (< or ≥ 75 years of age). For this purpose, we will use the R randomizeR package using two block sizes (4 and 6) with random permutation. The randomisation sequence will be generated by a unit (the Navarrabiomed Clinical Trials Platform) independent from the researchers who will recruit patients and implement the protocol. BLINDING (MASKING): The study will be quadruple-blinded, specifically, with blinding of patients, intervention providers, outcome assessors and data managers. The pharmacy at each participating hospital will prepare indistinguishable bags of methylprednisolone or placebo (0.9% saline) for patients of the experimental and placebo groups, respectively. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): The percentage of patients with treatment failure (primary endpoint) is currently unknown. Assuming an absolute difference of 25% in the primary outcome between the two groups (35% in the control group and 10% in the intervention group), we estimate that 60 patients (30 per group) are required to detect this difference with a two-tailed type I error of 0.05 and a type II error of 0.2. Estimating a loss to follow-up of 20%, we should recruit a total sample size of 72 patients (36 per group). TRIAL STATUS: The Spanish Agency of Medicines and Medical Devices (AEMPS) and the Ethics Committee of the University Hospital La Princesa approved version 7.0 of the protocol on 30 April 2020 as a low intervention clinical trial. Subsequently, the protocol has been amended by researchers and re-approved by AEMPS and the same ethics committee on 1 July 2020 (version 8.0) and on 28 August 2020 (version 9.0). Currently, the trial is in the recruitment phase. Recruitment began on 28 May 2020 and is expected to be completed by February 2021. TRIAL REGISTRATION: This study protocol was registered on the eudract.ema.europa.eu on 5 May 2020 (title "Early treatment of COVID-19 pneumonia with glucocorticoids. Randomized controlled clinical trial"; EudraCT Number: 2020-001827-15 ) and on clinicaltrials.gov on 19 June 2020 (title: "Glucocorticoids in COVID-19 (CORTIVID)"; identifier: NCT04438980 ). FULL PROTOCOL: The full protocol (version 9.0) is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Les Bujanda I, Loureiro-Amigo J, Bastons FC, et al. Treatment of COVID-19 pneumonia with glucocorticoids (CORTIVID): a structured summary of a study protocol for a randomised controlled trial. Trials. 2021. PMID: 33430891. doi:10.1186/s13063-020-04999-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。